| Scott M. Terrillion |
Scott M. Terrillion is currently the Secretary & Chief Compliance Officer at CARA Therapeutics, Inc. He is also a Trustee at Albany College of Pharmacy & Health Sciences and a Member of the New York State Bar Association. Previously, he worked as the Director-Pharmancy at Preferred Care, Inc. from 1994 to 1998. From 2014 to 2016, he served as the Head-Compliance, VP & Associate General Counsel at Mesoblast, Inc. Prior to that, he was an Associate at Nixon Peabody LLP from 1990 to 1994. From 1998 to 2014, he held the position of Vice President & Associate General Counsel at Boehringer Ingelheim Pharmaceuticals, Inc. Mr. Terrillion obtained his undergraduate degree from Albany College of Pharmacy & Health Sciences and his graduate degree from Albany Law School. |
| Joana Goncalves |
Joana Goncalves is the Chief Medical Officer at CARA Therapeutics, Inc. She previously worked as the Vice President-Medical Affairs & Neurology at Celgene Corp. and as the VP-Medical Strategy & Scientific Affairs at Leo Pharma, Inc. She earned a doctorate degree from the University of Cape Town. |
| Richard Makara |
Richard Makara is the founder of The Growth Engineering Co Oy. He is currently working as the Vice President, Head-Accounting & Controller at CARA Therapeutics, Inc. His current job started in 2022. Mr. Makara completed his undergraduate degree at Purdue University. |
| Frèdèrique Menzaghi |
Founder of CARA Therapeutics, Inc. and Sibia Neurosciences, Inc., Frèdèrique Menzaghi presently holds the position of Chief Scientific Officer, Senior VP-R&D at CARA Therapeutics, Inc.
In her past career she occupied the position of Principal at Eli Lilly & Co., Vice President-Pharmacology & Business Development at Psychogenics, Inc., Director-Preclinical Research Laboratory at Sibia Neurosciences, Inc. and Director-In Vivo Pharmacology at Arena Pharmaceuticals, Inc.
Frèdèrique Menzaghi received a graduate degree from Ecole des Mines de Nancy and a doctorate from the University of Strasbourg. |
| Ryan D. Maynard |
Ryan D. Maynard is currently serving as the Chief Financial Officer at CARA Therapeutics, Inc. since 2022 and as an Independent Director at Iovance Biotherapeutics, Inc. since 2015. He also holds the position of Chief Financial Officer at Paulus (Holdings) Ltd. Additionally, Mr. Maynard has previously worked as the Controller, Director-Finance & Accounting at Personify, Inc. (California) from 1999 to 2001, Senior Manager-Finance at Siliconix, Inc. from 1994 to 1998, Controller at General Magic, Inc. from 1998 to 1999, CFO, Executive VP & Head-Investor Relations at Rigel Pharmaceuticals, Inc. from 2001 to 2017, Chief Financial Officer at Blade Therapeutics, Inc. from 2018 to 2019, and Chief Financial Officer at LetsGetChecked, Inc. from 2019 to 2022. Mr. Maynard completed his undergraduate degree at Santa Clara University. |
| Iris Francesconi |
Iris Francesconi is currently the Chief Strategy Officer & Head-Investor Relations at CARA Therapeutics, Inc. She previously worked as an Analyst at Piper Sandler Ltd., UBS Warburg (UK), and Landesbank Baden-Württemberg (Broker) in 2005. She also served as the Head-Marketing, Market Research & Commercial at BioXcel Therapeutics, Inc. Dr. Francesconi holds a doctorate degree from Georgia State University, an MBA from Cornell University, and undergraduate and graduate degrees from Graz University of Technology. |
| Martin A. Vogelbaum |
Martin A. Vogelbaum is the founder of Gloucester Pharmaceuticals, Inc. He currently holds the position of Chief Executive Officer at Ajax Therapeutics, Inc. Additionally, he is the Chairman at CARA Therapeutics, Inc. since 2022. He is also the Director & Managing Partner at Inning One Ventures LP. Previously, he served as a Partner at Rho Capital Partners, Inc. starting in 2005. He also worked as an Advisor at The New York City Investment Fund Manager, Inc. and as a Non-Managing Member at RMV VI LLC. In terms of former positions, Mr. Vogelbaum served as a Director at Nuvelo, Inc. from 1997 to 2005. He was also a Director at Middlebrook Pharmaceuticals, Inc. from 2007 to 2010. From 2010 to 2016, he held the position of Independent Director at Inotek Pharmaceuticals Corp. He has also served as a Director at Mersana Therapeutics, Inc., AqueSys, Inc., and SARcode Bioscience, Inc. Additionally, he was a Director at Medpace Research, Inc. from 2013 to 2014 and a Director at Nora Therapeutics, Inc. Furthermore, he worked as the Vice President-Business Development at Celgene Corp. from 2015 to 2017. He has also held the position of General Partner at Oxford Bioscience Partners and Apple Tree Venture Management LLC. Moreover, he worked as an Associate at Memorial Sloan Kettering Cancer Center. Mr. Vogelbaum completed his undergraduate degree at The Trustees of Columbia University in The City of New York. |
| Christopher A. Posner |
Christopher A. Posner is currently the President, Chief Executive Officer & Director at CARA Therapeutics, Inc. Prior to his current position, he served as the President & Chief Executive Officer at Leo Pharma, Inc. from 2017 to 2021. He also held the position of Head-Worldwide Commercial Operations at R-Pharm US LLC from 2014 to 2017. Mr. Posner has an undergraduate degree from Villanova University and an MBA from The Fuqua School of Business. |
| Lisa von Moltke |
Lisa von Moltke is an Independent Director at CARA Therapeutics, Inc. since 2022 and the Chief Medical Officer & Executive Vice President at Seres Therapeutics, Inc. since 2020. She previously worked as the Head-Translational Medicine at Millennium Pharmaceuticals, Inc. from 2002 to 2009. In 2012 to 2016, she served as the President of the American College of Clinical Pharmacology. Lisa also held positions as Vice President-Clinical Pharmacology at Sanofi Corp. and Genzyme Corp., and as Senior Vice President-Clinical Development at Alkermes Plc. She completed her undergraduate degree at Wellesley College and obtained her doctorate from Michigan State University College of Human Medicine. |
| Susan Patricia Shiff |
Susan Patricia Shiff is an Independent Director at CARA Therapeutics, Inc. She is also a Director at Merck Global Health Innovation Fund LLC, Synthace Ltd., and a Trustee at New Jersey Symphony Orchestra. Previously, she served as a Senior Vice President at Merck & Co., Inc. from 2014 to 2021. She also held positions as a Vice President at Pfizer Inc. and Teva Pharmaceutics. In addition, she was the President of Ontada LLC from 2021 to 2023. Dr. Shiff holds a doctorate degree from the University of California, Los Angeles and an MBA from Cornell University. |
| Jeffrey L. Ives |
Jeffrey L. Ives is currently serving as an Independent Director at Acumen Pharmaceuticals, Inc., CARA Therapeutics, Inc., Pinteon Therapeutics, Inc., Astrocyte Pharmaceuticals, Inc., and New Leaf Venture Partners LLC. He is also a Principal at Neuropharma Advisors LLC. Previously, he held the position of Chief Executive Officer & Director at Satori Pharmaceuticals, Inc. from 2009 to 2013. He also worked as a Director & Vice President-Business Development at Celgene Corp. Additionally, he served as a Senior Vice President at Pfizer Inc. from 2001 to 2007 and as an Executive-in-Residence at Puretech Health LLC. He was also a Senior Vice President-Research Portfolio at Pfizer (St. Louis) from 2001 to 2007. Dr. Ives completed his undergraduate degree at Colgate University and holds graduate and doctorate degrees from Yale University. |
